Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder

Sleep Medicine

Volumn 11, Issue 4, 2010, Pages 361-365

  Iwanami, Masaoki ^a   Miyamoto, Tomoyuki ^a   Miyamoto, Masayuki ^a   Hirata, Koichi ^a   Takada, Etsuo ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Hyperechogenicity; Idiopathic REM sleep behavior disorder (RBD); Odor Stick Identification Test for Japanese (OSIT J); Parkinson disease; Substantia nigra; Transcranial sonography

Indexed keywords

ADULT; AGED; ANOSMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; HYPOSMIA; JAPANESE; MALE; OLFACTORY DISCRIMINATION; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; AROUSAL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; NEURODEGENERATIVE DISEASES; ODORS; OLFACTION DISORDERS; REM SLEEP BEHAVIOR DISORDER; SUBSTANTIA NIGRA;

EID: 77949911937     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2009.12.006     Document Type: Article

References (49)

1. Schenck C.H., Mahowald M.W. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in sleep. Sleep 2002, 25:120-138.
2. Gagon J.F., Bedard M.A., Fantini M.L., et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002, 59:585-589.
3. Albin R.L., Koeppe R.A., Chervin R.D., et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000, 55:1410-1412.
4. Eisensehr I., Linke R., Noachtar S., Schwarz J., Gildehaus F.J., Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000, 123:1155-1160.
5. Becker G., Seufert J., Bogdahn U., Reichmann H., Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995, 45:182-184.
6. Weise D., Lorenz R., Schliesser M., Schirbel A., Reiners K., Classen J. Substantia nigra echogenicity: a structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease. Mov Disord 2009, 24:1669-1675.
7. Unger M.M., Möller J.C., Stiasny-Kolster K., et al. Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord 2008, 23:596-599.
8. Stockner H., Iranzo A., Seppi K., et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009, 24:1906-1909.
9. Unger M.M., Möller J.C., Ohletz T., Stiasny-Kolster K., Oertel W.H., Mayer G. Transcranial midbrain sonography in narcoleptic subjects with and without concomitant REM sleep behaviour disorder. J Neurol 2009, 256:874-877.
10. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996, 46:388-393.
11. Schenck C.H., Bundlie S.R., Mahowald M.W. REM behavior disorder (RBD): delayed emergence of parkinsonism and/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum & maximum tonic and/or phasic electromyographic abnormalities found during REM sleep. Sleep 2003, 26(Suppl.):A316.
12. Iranzo A., Molinuevo J.L., Santamaria J., et al. Rapid-eye-movement sleep behavior disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006, 5:572-577.
13. Iranzo A., Molinuevo J.L., Santamaria J., et al. Sixty-four percent of patients with idiopathic REM sleep behavior disorder developed a neurological disorder after a mean clinical follow-up of seven years. Sleep 2008, 31(Suppl.):A280.
14. Postuma R.B., Gagnon J.F., Vendette M., Fantini M.L., Massicotte-Marquez J., Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009, 72:1296-1300.
15. Braak H., Del Tredici K., Rüb U., de Vos R.A.I., Jansen Steur E.N.H., Braak E. Staging of pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
16. Turner R.S., Chervin R.D., Frey K.A., Minoshima S., Kuhl D.E. Probable diffuse Lewy body disease presenting as REM sleep behavior disorder. Neurology 1997, 49:523-527.
17. Turner R.S., D'Amato C.J., Chervin R.D., Blaivas M. The pathology of REM sleep behavior disorder with comorbid Lewy body dementia. Neurology 2000, 55:1730-1732.
18. Uchiyama M., Isse K., Tanaka K., et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology 1995, 45:709-712.
19. Boeve B.F., Silber M.H., Saper C.B., et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007, 130:2770-2788.
20. Walter U., Klein C., Hilker R., Benecke R., Pramstaller P.P., Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 2004, 19:1445-1449.
21. American Academy of Sleep Medicine. The international classification of sleep disorders, 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005. p. 148-152.
22. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
23. Fahn S., Elton R.L. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease 1987, 153-163. MacMillan, New Jersey. S. Fahn, M. Goldstein, D. Marsden, D.B. Calne (Eds.).
24. American Psychiatric Association. DSM-IV-TR. Diagnostic and statistical manual of mental disorders, 4th ed. Text revision. Washington, DC: American Psychiatric Association; 2000.
25. Bleecker M.L., Bolla-Wilson K., Kawas C., et al. Age-specific norms for the mini-mental state exam. Neurology 1988, 38:1565-1568.
26. Rechtschaffen A., Kales A. A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects 1968, UCLA Brain Information Service/Brain Research Institute, Los Angeles.
27. Schmidauer C., Sojer M., Seppi K., et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 2005, 58:630-634.
28. Berg D., Becker G., Zeiler B., et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999, 53:1026-1031.
29. Berg D., Siefker C., Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001, 248:684-689.
30. Doepp F., Plotkin M., Siegel L., et al. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. Mov Disord 2008, 23:405-410.
31. Spiegel J., Hellwig D., Möllers M.O., et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006, 129:1188-1193.
32. Walter U., Hoeppner J., Prudente-Morrissey L., Horowski S., Herpertz S.C., Benecke R. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007, 130:1799-1807.
33. Kobayashi M., Saito S., Kobayakawa T., Deguchi Y., Costanzo R.M. Cross-cultural comparison of data using the odor stick identification test for Japanese (OSIT-J). Chem Senses 2006, 31:335-342.
34. Miyamoto T., Miyamoto M., Iwanami M., Suzuki K., Inoue Y., Hirata K. Odor identification as an indicator of idiopathic REM sleep behavior disorder. Mov Disord 2009, 24:268-273.
35. Saito S, Kobayakawa T, Ayabe-Kanamura S. Distribution of the odor identification scores measured by " OSIT-J" in healthy Japanese people, The 42nd Annual Meeting of the Japanese Association for the Study of Taste and Smell; 2008.
36. Kajimoto Y., Miwa H., Okawa-Izawa M., Hironishi M., Kondo T. Transcranial sonography of the substantia nigra and MIBG myocardial scintigraphy: complementary role in the diagnosis of Parkinson's disease. Parkinsonism Relat Disord 2009, 15:270-272.
37. Gaenslen A., Unmuth B., Godau J., et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008, 7:417-424.
38. Berg D., Merz B., Reiners K., Naumann M., Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005, 20:383-385.
39. Berg D., Roggendorf W., Schröder U., et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002, 59:999-1005.
40. Zecca L., Berg D., Arzberger T., et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005, 20:1278-1285.
41. Behnke S., Schroeder U., Dillmann U., et al. Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. NeuroImage 2009, 47:1237-1243.
42. Doty R.L., Deems D.A., Stellar S. Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988, 38:1237-1244.
43. Doty R.L., Stern M.B., Pfeiffer C., Gollomp S.M., Hurtig H.I. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992, 55:138-142.
44. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.L., Wolters E.C., Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004, 56:173-181.
45. Ross G.W., Petrovitch H., Abbott R.D., et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008, 63:167-173.
46. Haehner A., Hummel T., Hummel C., Sommer U., Junghanns S., Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Diord 2007, 22:839-842.
47. Stiasny-Kolster K., Doerr Y., Möller J.C., et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005, 128:126-137.
48. Gaig C., Tolosa E. When does Parkinson's disease begin?. Mov Disord 2009, 24:S656-S664.
49. Okawa M., Miwa H., Kajimoto Y., et al. Transcranial sonography of the substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism: clinical potential and limitations. Intern Med 2007, 46:1527-1531.